Combining an antimuscarinic with a beta-3 adrenoceptor agonist could improve the symptoms of overactive bladder (OAB), while allowing a lower dose of antimuscarinic and thus reducing side effects, results of an early study suggest. A total of 1,306 patients, at 141 centres across 20 European countries, were randomised in this study. Two-thirds of the patients were women, and all had had symptoms of OAB for 3 months or longer.  [With external links to the current evidence base]